Navigation Links
Nektar Therapeutics Reports Second Quarter 2011 Financial Results
Date:8/4/2011

SAN FRANCISCO, Aug. 4, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2011.

Cash, cash equivalents, and investments at June 30, 2011 were $481.8 million as compared to $315.9 million at December 31, 2010.

Revenue for the second quarter of 2011 decreased to $17.3 million as compared to $42.6 million in the second quarter of 2010.  This decrease in revenue year over year is primarily attributable to the completion as of December 31, 2010 of the amortization of the $125.0 million upfront payment received in 2009 from AstraZeneca for the NKTR-118 and NKTR-119 license agreement.  

“Nektar continued to advance our pipeline programs in the second quarter of 2011,” said Howard W. Robin, President and Chief Executive Officer of Nektar. “In June, we finalized our pivotal study design for NKTR-102 in metastatic breast cancer with the FDA. AstraZeneca’s Phase 3 KODIAC program for NKTR-118 is continuing with the first regulatory filing planned for 2013.  We completed our first clinical study of NKTR-181, our novel opioid candidate, with positive proof-of-concept results.  Finally, we are on track to introduce a new IND candidate later this year.”

Total operating costs and expenses in the second quarter of 2011 increased by 27% to $51.6 million, compared to $40.7 million in the second quarter of 2010.  This increase was primarily a result of higher development expenses related to the advancement of multiple programs in clinical development.  Research and development expense increased to $32.3 million in the second quarter of 2011 as compared to $25.6 million for the second quarter in 2010.  General and administrative expense increased to $11.2 million in the second quarter of 2011 from $10.2 million in the second quarter
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
3. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
4. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
5. Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
8. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
10. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
11. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... -- Dedicated to promoting wellness and giving back to its ... purple pledge in support of Alzheimer,s & Brain-Awareness Month. ... time to shine a purple light for the millions ... in our community who are affected by Alzheimer,s. Raising ... helps mobilize friends, family members, neighbors and coworkers to ...
(Date:7/7/2015)... -- The Global Breast Pumps Market ... at an estimated CAGR of 7.6% from 2014 to 2020, ... Introduction of innovative technologies including hand free breast pumps, growing ... the advantages of breast milk are expected to drive breast ... of untapped growth opportunities in emerging markets such as ...
(Date:7/7/2015)... , July 7, 2015  Essentialis, a venture-backed company focused ... the treatment of orphan neurobehavioral and metabolic diseases, today announced ... will present a corporate update at the Cantor Fitzgerald Inaugural ... Date: Wednesday, July 8, 2015 Time: 8:00 AM ... About Essentialis, Inc. Essentialis is ...
Breaking Medicine Technology:Purple for a Purpose: Supporting Alzheimer's & Brain-Awareness Month 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4
... 10, 2011 The American Society of Bariatric Physicians (ASBP) ...  Our condolences go out to his family, friends and fans. ... phentermine was a contributing factor to his death are concerning ... medications as prescribed. While the specific details ...
... Sciences International, Inc. (Nasdaq: BDSI ) ... study of a formulation of buprenorphine and naloxone ... technology.   (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) ... to select the final doses of BEMA Buprenorphine/Naloxone ...
Cached Medicine Technology:Physicians Who Treat Obesity Respond to the News of Bubba Smith's Overdose 2BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone 2BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone 3BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone 4
(Date:7/7/2015)... ... July 07, 2015 , ... Catalent, ... development solutions for drugs, biologics and consumer health products, today announced that ... its antibody combination therapy (ACT) technology platform. The platform has the potential ...
(Date:7/7/2015)... ... 2015 , ... Safe Catch is setting revolutionary purity limits for canned tuna ... New Leaf Community Markets, Sprouts Farmers Market and Wegmans are some of the first ... every fish for mercury,” said Safe Catch co-founder Sean Wittenberg. “We launched Safe Catch ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... the experience for its patient community using its IDF ePHR, an electronic personal ... primary immunodeficiency diseases (PI) to easily track their health information, including symptoms, diagnoses, ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... On Saturday, ... golf outing at the Manistee Golf and Country Club. Best Drug Rehabilitation staff members ... a good cause, helping underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis ...
(Date:7/7/2015)... ... July 07, 2015 , ... On June 22nd-26th, 2015, the ... the National Baptist Convention 110th Annual Session of the National Baptist Congress of ... of churches and their congregations, medical professionals and health-related organizations, this week long ...
Breaking Medicine News(10 mins):Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Safe Catch Launches Tuna with Lowest Mercury Limit of Any Brand 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 3
... soon have a legal framework in place for creating a DNA ... such a database and its admissibility in courts as evidence is ... ,The first draft of the bill is being circulated ... will be presented to the cabinet before it is tabled in ...
... responsible for killing up to half a million Ethiopian ... condition and includes children who are 70 percent or ... height measurements., ,Malnutrition is also a major concern ... What is all the more alarming is that acute ...
... research shows that drinking coffee could decrease the risk ... cohort studies that showed self-reported frequency of coffee consumption ... for potential confounders, researchers say they found that those ... 30 per cent, while those drinking one or more ...
... substitute to her milk’,// . ,Breast feeding has been ... UNICEF and breast feeding steering committees as a socially acceptable ... 1-7)’ comes to an end of weeklong campaign, the United ... many countries. While in some countries it applauds the efforts, ...
... of ones appearance, their a large demand for slimming products ... ,The survey also shows that slimming products in Belgium grew ... a retail value of €29 million. , ,Despite the ... of obesity, the main driver of growth in slimming products ...
... working on using virtual reality to help patients deal ... this research, scientists are creating simulating virtual realities that ... the similar experiences they had felt when they had ... left them unable to cope reality. Called exposure therapy, ...
Cached Medicine News:Health News:DNA Directory Under Construction For Indian Criminals ! 2Health News:With More Appearance Conscious Consumers The Need For Slimming Products Is Rapidly Rising 2
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
Medicine Products: